PSMB9
ENSG00000240065
Target class
Enzyme
Chromosome
6
Approved drugs
3
Clinical candidates (approved and in development)
6
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- Yes
- Target name
- PSMB9
- Gene name
- Proteasome 20S subunit beta 9
- Gene symbol
- PSMB9
- Previous gene symbols
- LMP2
- Protein name
- Proteasome subunit beta type-9 (EC 3.4.25.1) (Low molecular mass protein 2) (Macropain chain 7) (Multicatalytic endopeptidase complex chain 7) (Proteasome chain 7) (Proteasome subunit beta-1i) (Really interesting new gene 12 protein)
- RING12
- beta1i
- PSMB6i
- Gene biotype
- Protein coding
- Gene family
- Proteasome
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 537.05
- Tissue specificity (Gini)
- 0.539
- Tissue specificity (tau)
- 0.926
- KEGG gene identifiers
- hsa:5698
- Protein interaction confidence
- 0.902184
- Protein interaction partners
- 76
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-9907900
- R-HSA-9912633
- End position
- 32860734
- Start position
- 32844136
- Chromosome
- 6
- Strand
- Forward
- Cytoplasm . Nucleus .
- Cytosol
- Tissue specificity (tau)
- 0.925998
- Expression inequality (Gini)
- 0.538871
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 537.05
- Spleen
- 236.52
- Whole Blood
- 182.6
- Small Intestine - Terminal Ileum
- 116.31
- Lung
- 105.18
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes537.05
- Spleen236.52
- Whole Blood182.6
- Small Intestine - Terminal Ileum116.31
- Lung105.18
- Nerve - Tibial67.36
- Adipose - Subcutaneous66.65
- Adipose - Visceral (Omentum)65.37
- Uterus61.52
- Breast - Mammary Tissue60.13
- Fallopian Tube54.57
- Vagina51.36
- Cervix - Endocervix51.31
- Thyroid49.37
- Cervix - Ectocervix48.49
- Colon - Transverse45.07
- Kidney - Medulla42.81
- Artery - Coronary42.8
- Prostate42.54
- Bladder40.33
- Skin - Not Sun Exposed (Suprapubic)36.62
- Adrenal Gland35.63
- Skin - Sun Exposed (Lower leg)34.32
- Cells - Cultured fibroblasts34.17
- Ovary34.13
And 29 more, listed on the interactive page.
Biological processes
- GO:0043161
- GO:0000502
- GO:0005829
- GO:0070062
Molecular functions
- GO:0005515
Related records
Trials (799)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (6)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Marizomib 20S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor